Chemomab Therapeutics (CMMB) Non-Current Assets (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Non-Current Assets data on file, last reported at $387000.0 in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Assets fell 58.12% year-over-year to $387000.0; the trailing twelve-month figure through Dec 2025 stood at $387000.0 (down 58.12% YoY), and the FY2025 full-year result was $387000.0, down 58.12% from the prior year.
• Non-Current Assets for Q4 2025 stood at $387000.0, down from $442000.0 in the prior quarter.
• Across five years, Non-Current Assets topped out at $1.7 million in Q2 2021 and bottomed at $387000.0 in Q4 2025.
• The 5-year median for Non-Current Assets is $1.2 million (2023), against an average of $1.1 million.
• The widest annual swing landed in 2021, when Non-Current Assets surged 430.9%; it then tumbled 58.12% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $1.7 million in 2021, then fell by 20.3% to $1.3 million in 2022, then fell by 5.5% to $1.3 million in 2023, then fell by 26.32% to $924000.0 in 2024, then sank by 58.12% to $387000.0 in 2025.
• The last three Non-Current Assets figures came in at $387000.0 (Q4 2025), $442000.0 (Q3 2025), and $515000.0 (Q2 2025), per Business Quant data.

Peer Comparison